From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

OptiBiotix – long-winded “Strategic and commercial update”, but various positives suggest still a Strong Buy with target price increased

By Tom Winnifrith & Steve Moore | Wednesday 28 February 2024

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

OptiBiotix Health (OPTI) has issued a “Strategic and commercial update” announcement. There are various positives in the long-winded announcement and the shares have currently responded more than 11% higher to 25p, but that’s still below levels of even early this month and we’d have preferred a much more to-the-point announcement of financials and orders news. However, having spoken to CEO Stephen O’Hara, we believe significant progress is being made on those to mean significant potential from the current £22.8 million market capitalisation.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Anpario – a recovery Buy?...

Thursday »


Bearcast issue update: all should be well



Oracle Power: Cynical Foul

Time left: 13:24:34